» Articles » PMID: 15205313

Adenovirus-mediated Expression of Antisense Urokinase Plasminogen Activator Receptor and Antisense Cathepsin B Inhibits Tumor Growth, Invasion, and Angiogenesis in Gliomas

Overview
Journal Cancer Res
Specialty Oncology
Date 2004 Jun 19
PMID 15205313
Citations 35
Authors
Affiliations
Soon will be listed here.
Abstract

We have shown previously that urokinase plasminogen activator receptor (uPAR) and cathepsin B are overexpressed during glioma progression, particularly at the leading edge of the tumor. In the present study, we simultaneously down-regulated uPAR and cathepsin B in SNB19 glioma cell monolayer or SNB19 spheroids using an adenoviral vector carrying antisense uPAR and antisense cathepsin B and a combination of these genes as determined by Western blot analysis. The Ad-uPAR-Cath B-infected cells revealed a marked reduction in tumor growth and invasiveness as compared with the parental and vector controls. In vitro and in vivo angiogenic assays demonstrated inhibition of capillary-like structure formation and microvessel formation after Ad-uPAR-Cath B infection of SNB19 cells when compared with Ad-cytomegalovirus (CMV)-infected or mock-infected controls. Furthermore, using a near infrared fluorescence probe, in vivo imaging for cathepsin B indicated low/undetectable levels of fluorescence after injection of the Ad-uPAR-Cath B construct into pre-established s.c. tumors as compared with Ad-CMV-treated and untreated tumors. The effect with bicistronic construct (Ad-uPAR-Cath B) was much higher than with single (Ad-uPAR/Ad-Cath B) constructs. These results indicate that the down-regulation of cathepsin B and uPAR plays a significant role in inhibiting tumor growth, invasion, and angiogenesis. Hence, the targeting of these two proteases may be a potential therapy for brain tumors and other cancers.

Citing Articles

Cell-specific cross-talk proteomics reveals cathepsin B signaling as a driver of glioblastoma malignancy near the subventricular zone.

Norton E, Whaley L, Jones V, Brooks M, Russo M, Morderer D Sci Adv. 2024; 10(32):eadn1607.

PMID: 39110807 PMC: 11305394. DOI: 10.1126/sciadv.adn1607.


Smart Delivery Systems Responsive to Cathepsin B Activity for Cancer Treatment.

Egorova V, Kolesova E, Lopus M, Yan N, Parodi A, Zamyatnin Jr A Pharmaceutics. 2023; 15(7).

PMID: 37514035 PMC: 10386206. DOI: 10.3390/pharmaceutics15071848.


Urokinase-type plasminogen activator receptor (uPAR) as a therapeutic target in cancer.

Zhai B, Tian H, Sun J, Zou J, Zhang X, Cheng J J Transl Med. 2022; 20(1):135.

PMID: 35303878 PMC: 8932206. DOI: 10.1186/s12967-022-03329-3.


Tumor Cell Infiltration into the Brain in Glioblastoma: From Mechanisms to Clinical Perspectives.

Seker-Polat F, Pinarbasi Degirmenci N, Solaroglu I, Bagci-Onder T Cancers (Basel). 2022; 14(2).

PMID: 35053605 PMC: 8773542. DOI: 10.3390/cancers14020443.


Cysteine cathepsins B, X and K expression in peri-arteriolar glioblastoma stem cell niches.

Breznik B, Stokin C, Kos J, Khurshed M, Hira V, Bosnjak R J Mol Histol. 2018; 49(5):481-497.

PMID: 30046941 PMC: 6182580. DOI: 10.1007/s10735-018-9787-y.